ALLO News and Press, Allogene Therapeutics Inc. From 05/12/22

Gene editing biotech, Caribou Biosciences (NASDAQ:CRBU) has recorded the best intraday gain on Thursday after releasing Phase 1 data for its allogeneic anti-CD19 CAR-T cell therapy, CB-010 in relapsed or refractory B cell non-Hodgkin lymphoma. Noting the favorable early results, SVB Leerink h...

Allogeneic CAR T Pioneer Highest Ranked Bay Area Biotech in the Large Company Category Based on Employee Survey SOUTH SAN FRANCISCO, Calif., May 09, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the develo...

Allogene Therapeutics, Inc. (ALLO) Q1 2022 Earnings Conference Call May 04, 2022 05:00 PM ET Company Participants Christine Cassiano - Chief Communications Officer David Chang - President and Chief Executive Officer Rafael Amado - EVP of Research and Development and Chief Medical Officer Eric...

Allogene Therapeutics press release (NASDAQ:ALLO): Q1 GAAP EPS of -$0.56 beats by $0.02. Ended First Quarter with $733 Million in Cash, Cash Equivalents and Investments Outlook: Allogene continues to expect full year GAAP Operating Expenses to be between $360 million and $390 million inc...

Pivotal Phase 2 ALPHA2 Trial of ALLO-501A in R/R Large B Cell Lymphoma Planned to Commence Mid 2022 Using Product from Cell Forge 1 (CF1) CF1 is Projected to Support the Manufacture of ~20,000 Doses of AlloCAR T™ Products Annually at Scale Clinical Updates from the CD19...

New Position Aimed at Attracting, Retaining, and Cultivating a Best-in-Class Workforce as Allogene Scales its Operations for its Next Stage of Growth SOUTH SAN FRANCISCO, Calif., April 28, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotec...

The U.S. FDA has granted Orphan Drug Designation to Allogene Therapeutics' (NASDAQ:ALLO) multiple myeloma candidate ALLO-605. The allogeneic CAR T asset is currently in phase 1 targeting B cell maturation antigen (BCMA). ALLO-605 was granted Fast Track status in Q2 2021. Allogene (ALLO) ...

Conference Call and Webcast Scheduled for 2:00 PM PT/5:00 PM ET SOUTH SAN FRANCISCO, Calif., April 27, 2022 (GLOBE NEWSWIRE) -- Allogene Therapeutics, Inc. (Nasdaq: ALLO), a clinical-stage biotechnology company pioneering the development of allogeneic CAR T (AlloCAR T™) pro...

ODD Follows FDA Fast Track Designation Granted for ALLO-605 in Q2 2021 ALLO-605 is in Phase 1 in the IGNITE Trial and Part of Allogene’s Multi-Pronged Strategy Targeting BCMA BCMA Program Clinical Updates are Planned for Late 2022 SOUTH SAN FRANCISCO, Calif., Apri...

FN Media Group Presents Microsmallcap.com Market Commentary New York, NY – April 21, 2022 – Resistance to antibiotics is a growing concern. About 750,000 people die each year worldwide from drug–resistance infections. If solutions aren’t found and...